Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical potential of mannose-binding lectin-replacement therapy.

J A Summerfield1

  • 1Division of Medicine, Faculty of Medicine, Imperial College London, St Mary's Campus, London W2 1NY, UK. j.Summerfield@imperial.ac.uk

Biochemical Society Transactions
|July 31, 2003
PubMed
Summary

Mannose-binding lectin (MBL) deficiency, genetically determined, is linked to infections and autoimmune diseases. MBL therapy shows potential for treating these conditions but requires further clinical trials for safety and efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrent miscarriage and variant alleles of mannose binding lectin, tumour necrosis factor and lymphotoxin alpha genes.

Clinical and experimental immunology·2001
Same author

Virus hepatitis update.

Journal of the Royal College of Physicians of London·2000
Same author

Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group.

Lancet (London, England)·1999
Same author

Mannose-binding protein in HIV-seropositive patients does not contribute to disease progression or bacterial infections.

International journal of STD & AIDS·1998
Same author

Fractured rib, pleural effusion and ascites.

Lancet (London, England)·1998
Same author

Pancreatic abnormalities and AIDS related sclerosing cholangitis.

Genitourinary medicine·1997

Area of Science:

  • Immunology
  • Genetics

Background:

  • Mannose-binding lectin (MBL) is a key innate immunity component.
  • MBL levels are primarily genetically determined, with deficiency linked to various infections and non-infectious diseases like rheumatoid arthritis and cystic fibrosis.

Purpose of the Study:

  • To explore the role of MBL deficiency in disease susceptibility and progression.
  • To evaluate the potential therapeutic applications of MBL (plasma-derived or recombinant) therapy.

Main Methods:

  • Review of existing literature on MBL deficiency and its clinical associations.
  • Discussion of potential benefits and risks of MBL therapy.

Main Results:

  • MBL deficiency is associated with increased susceptibility to infections and altered disease natural history (e.g., rheumatoid arthritis, cystic fibrosis).

Related Experiment Videos

  • MBL therapy may offer benefits in MBL-deficient individuals for infection recovery and as a disease-modifying drug.
  • Potential risks include enhanced complement-mediated host damage.

    • Conclusions:

    • MBL therapy holds promise for managing infections and certain chronic diseases, particularly in MBL-deficient patients.
    • Further randomized controlled clinical trials are essential to establish the safety and efficacy of MBL therapy.